Altimmune to Participate at Two Upcoming Investor Conferences

August 30, 2023 at 7:30 AM EDT

GAITHERSBURG, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:

  • Wells Fargo 2023 Healthcare Conference in Everett, MA
    Wednesday, September 6, 2023
    Fireside chat at 3:45 pm Eastern Time
  • Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY
    Wednesday, September 13, 2023
    Fireside chat at 1:35 pm Eastern Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450


Primary Logo

Source: Altimmune, Inc


Investor Contact

Richard Eisenstadt
Chief Financial Officer



Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail